Loading page…

Bacil Pharma Ltd (BACPHAR) · mywealthgrid

Bacil Pharma Ltd

BSE:BACPHAR

HealthcarePharmaceuticals & Biotechnology

₹27.3

+4.64%1 Oct close

Mkt cap

₹39 Cr

Watch Alert Compare

About

Bacil Pharma Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹39 Cr

P/E

97.2×

P/B

1.5×

Dividend yield

ROE

6.2%

ROCE

Debt / equity

OPM

—

EPS (TTM)

₹0.3

Book value

₹17.8

52-week high

—

52-week low

—

1,359 historical price candles were omitted because the exchange source has not been verified.

₹27.3+4.4%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of 1.3% (3-yr avg)
−Expensive at 97.2× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

33/100

Business quality: 35
Valuation: 32

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	—	—	—	—	—	0	0	0	0	—	0
	—	—	—	—	—	0	4	0	0	—	0
	—	—	—	—	—	-0	-4	-0	-0	—	-0
OPM %	—	—	—	—	—	—	—	—	—	—	—
Depreciation	—	—	—	0	0	0	0	0	0	—	0
Interest	—	—	—	—	—	0	0	0	0	—	0
	0	0	0	0	0	0	0	0	0	1	1
Profit before tax	-0	0	-4	-0	-0	-0	-4	-0	-0	0	1
Tax	—	—	—	—	—	0	0	0	0	—	-1
Tax %	—	—	—	—	—	0%	0%	0%	0%	—	-57.6%
	-0	0	-4	-0	-0	-0	-4	-0	-0	0	2
PAT margin %	—	—	—	—	—	—	—	—	—	—	—
EPS (₹)	-0.1	—	-6.4	-0.6	-0.5	-0.4	—	-0.2	-0.1	0.7	1.1
EPS adjusted (₹)	—	—	—	—	—	-0.4	-5.9	-0.2	-0.1	0.3	1.1
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	7	7	7	7	14	14
Reserves	-5	-5	-5	-5	11	11
	0	0	0	0	0	0
	3	0	0	0	0	3
Total equity & liabilities	4	1	1	1	26	27
	0	0	0	0	—	0
CWIP	—	—	—	—	—	0
Investments	0	0	0	1	21	24
	4	1	1	1	4	3
Total assets	4	1	1	1	26	27

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	-4	-0	0	0	2
	1	4	-0	0	0	-3
	-0	0	0	-0	2	-1
Net cash flow	0	0	-0	0	—	-2
Free cash flow	—	—	—	—	0	2
CFO / Operating profit %	—	—	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	—	—
EBITDA margin %	—	—	—	—	—	—	—	—
EBIT margin %	—	—	—	—	—	—	—	—
PAT margin %	—	—	—	—	—	—	—	—
Working capital
Receivable days	—	—	—	—	—	—	—	—
Inventory days	—	—	—	—	—	—	—	—
Payable days	—	—	—	—	—	—	—	—
NWC days	—	—	—	—	—	—	—	—
Leverage
Current ratio	—	—	0.11	10	7.67	0.45	—	0.68
Debt to EBITDA	—	—	—	—	—	—	—	—
Debt to equity	—	—	0.13	0.02	0.02	0.08	0.01	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0	0	0	0	—	0
Return ratios
Return on assets %	—	—	-5.9%	-303.9%	-8.8%	-4.5%	1.6%	5.7%
Return on capital employed %	—	—	-17.3%	-295.8%	-9.5%	-5.2%	—	4%
Return on equity %	—	—	-17.3%	-313.8%	-9.1%	-4.9%	1.6%	6.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	42.67%	42.67%	42.67%	42.67%	20.7%	10.6%	0.2%	0.2%	0.08%	0.08%	0%	0%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	57.33%	57.33%	57.33%	57.33%	79.3%	89.4%	99.8%	99.8%	99.92%	99.92%	100%	100%
No. of shareholders	—	—	—	—	—	—	—	—	7,431	7,431	7,226	7,326

Promoter holding down 42.67 percentage points since Sep 2023.

141 deals · 5 Sept 2024 – 30 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Sept 2026	SHRYNAX TRADING PRIVATE LIMITED	Bulk	BSE	Buy	1,36,317	₹25.50	₹0.35 Cr
15 Sept 2026	HEMANGRAJENDRADOSHI	Bulk	BSE	Sell	83,531	₹20.14	₹0.17 Cr
28 Aug 2026	BRENLEY ENGINEERS PRIVATE LIMITED	Bulk	BSE	Buy	84,658	₹11.67	₹0.10 Cr
20 Aug 2026	VISHAL MAHESH WAGHELA	Bulk	BSE	Sell	80,000	₹11.71	₹0.09 Cr
19 Aug 2026	JR SEAMLESS PRIVATE LIMITED	Bulk	BSE	Buy	5,26,835	₹11.26	₹0.59 Cr
19 Aug 2026	MNM STOCK BROKING PVT. LTD.	Bulk	BSE	Sell	2,50,000	₹11.26	₹0.28 Cr
19 Aug 2026	PURSHOTTAM RAMESHWAR BOHRA	Bulk	BSE	Buy	2,10,445	₹11.26	₹0.24 Cr
19 Aug 2026	RAJESH HIRANI	Bulk	BSE	Sell	1,40,000	₹11.26	₹0.16 Cr
19 Aug 2026	DINESH ISHVARBHAI LALWANI	Bulk	BSE	Sell	1,27,448	₹11.44	₹0.15 Cr
19 Aug 2026	CHETVANI VINOD	Bulk	BSE	Sell	1,20,920	₹11.43	₹0.14 Cr

1–10 of 141

1 / 15

Manmohan GhildyalManager
Ganpat Dhondu SalekarManager
Mrs. CHAITALI KALPATARU SHAHExecutive Director-Chairperson
Ms. AVANI SAVJIBHAI GODHANIYANon-Executive - Independent Director
Mr. DINESH CHANDER NOTIYALNon-Executive - Independent Director
Mr. OMPRAKASH PYARELAL SONARNon-Executive - Independent Director
Mr. Vivek Mukesh YadavNon-Executive - Independent Director
Mr. Omprakash Pyarelal SonarNon-Executive - Independent Director
Mr. VIVEK MUKESH YADAVNon-Executive - Independent Director
Mr. Dikshant Singh PanwarCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Bacil Pharma Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

17 announcementsExport CSV

28 Jul 2026, 6:31 pmCompany Update

Announcement Under Regulation 30, LODR

General PDF

18 Jul 2026, 1:20 pmCompany Update

Attached Resignation Of Directors As Query Raised From BSE

General PDF

14 Jul 2026, 1:41 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

10 Jul 2026, 3:24 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

9 Jul 2026, 8:07 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

9 Jul 2026, 8:06 pmCompany Update

Announcement under Regulation 30 (LODR)-Raising of Funds

Raising of Funds PDF

9 Jul 2026, 8:05 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Outcome of Board Meeting PDF

7 Jul 2026, 7:16 pmCompany Update

Intimation Regarding Approval Of Name For Proposed Wholly-Owned Subsidiary

General PDF

Date	Category	Subject	Filing
28 Jul 2026, 6:31 pm	Company Update General	Announcement Under Regulation 30, LODR	PDF
18 Jul 2026, 1:20 pm	Company Update General	Attached Resignation Of Directors As Query Raised From BSE	PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	—	—
EBITDA margin %	—	—	—	—	—	—	—	—
EBIT margin %	—	—	—	—	—	—	—	—
PAT margin %	—	—	—	—	—	—	—	—
Working capital
Receivable days	—	—	—	—	—	—	—	—
Inventory days	—	—	—	—	—	—	—	—
Payable days	—	—	—	—	—	—	—	—
NWC days	—	—	—	—	—	—	—	—
Leverage
Current ratio	—	—	0.11	10	7.67	0.45	—	0.68
Debt to EBITDA	—	—	—	—	—	—	—	—
Debt to equity	—	—	0.13	0.02	0.02	0.08	0.01	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0	0	0	0	—	0
Return ratios
Return on assets %	—	—	-5.9%	-303.9%	-8.8%	-4.5%	1.6%	5.7%
Return on capital employed %	—	—	-17.3%	-295.8%	-9.5%	-5.2%	—	4%
Return on equity %	—	—	-17.3%	-313.8%	-9.1%	-4.9%	1.6%	6.3%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Bacil Pharma Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Board meetings1

No fund holdings on record

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded profit growth

Return on equity

1

1